IRVING, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. announced today that its Antioxidant Inflammation Modulator (AIM) CDDO-Im (also known as RTA 403) conferred protection to mice during chronic exposure to cigarette smoke, protecting against damage and related symptoms that cause chronic obstructive pulmonary disease (COPD) in a study published in the Proceedings of the National Academy of Sciences (January 6, 2009 issue) and featured in a “Research Highlights” review in Nature Reviews Drug Discovery (January 23, 2009 issue). The study was conducted by researchers at Johns Hopkins University, and Reata provided the AIM used in the study.
